Receptors, Tumor Necrosis Factor

"Receptors, Tumor Necrosis Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.

Descriptor ID	D018124
MeSH Number(s)	D12.776.543.750.705.852.760
Concept/Terms	Receptors, Tumor Necrosis Factor Receptors, Tumor Necrosis Factor Receptors, Cachectin Tumor Necrosis Factor Receptors TNF Receptor Receptor, TNF TNF Receptors Tumor Necrosis Factor Receptor Cachectin Receptors Receptors, TNF

Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, Immunologic [D12.776.543.750.705]
Receptors, Cytokine [D12.776.543.750.705.852]
Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]

Below are MeSH descriptors whose meaning is related to "Receptors, Tumor Necrosis Factor".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor" was a major or minor topic of these publications.

Bar chart showing 156 publications over 24 distinct years, with a maximum of 23 publications in 2002

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	0	4	4
1993	0	3	3
1994	0	1	1
1995	1	1	2
1996	3	1	4
1997	3	0	3
1998	5	1	6
1999	4	5	9
2000	4	2	6
2001	7	1	8
2002	9	14	23
2003	5	8	13
2004	5	9	14
2005	10	6	16
2006	9	6	15
2007	2	2	4
2008	1	5	6
2009	0	5	5
2010	3	2	5
2011	0	1	1
2012	1	3	4
2013	1	1	2
2014	0	1	1
2018	0	1	1

Below are the most recent publications written about "Receptors, Tumor Necrosis Factor" by people in Profiles.

Jindra PT, Cusick MF. Genetic Polymorphism in Cytokines and Costimulatory Molecules in Stem Cell and Solid Organ Transplantation. Clin Lab Med. 2019 03; 39(1):107-123.

View in: PubMed
Kimball AB, Rothman KJ, Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand JM. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol. 2015 Jan; 72(1):115-22.

View in: PubMed
Papadopoulou A, Krance RA, Allen CE, Lee D, Rooney CM, Brenner MK, Leen AM, Heslop HE. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther. 2014 Jun; 22(6):1134-1138.

View in: PubMed
Stange DE, Koo BK, Huch M, Sibbel G, Basak O, Lyubimova A, Kujala P, Bartfeld S, Koster J, Geahlen JH, Peters PJ, van Es JH, van de Wetering M, Mills JC, Clevers H. Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell. 2013 Oct 10; 155(2):357-68.

View in: PubMed
Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May 31; (5):CD004525.

View in: PubMed
Kimball AB, Pariser D, Yamauchi PS, Menter A, Teller CF, Shi Y, Yong M, Creamer K, Hooper M, Aras G, Kricorian G, Gelfand JM. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol. 2013 May; 68(5):756-64.

View in: PubMed
Bolaños-Meade J, Wu J, Logan BR, Levine JE, Ho VT, Alousi AM, Weisdorf DJ, Luznik L. Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302. Biol Blood Marrow Transplant. 2013 Mar; 19(3):481-5.

View in: PubMed
Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MG. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol. 2013 Apr; 133(4):1052-62.

View in: PubMed
Daniluk U, Kerros C, Tao RH, Wise JF, Ao X, Berkova Z, Samaniego F. The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells. J Exp Clin Cancer Res. 2012 Aug 28; 31:69.

View in: PubMed
Nguyen CM, Bounthavong M, Mendes MA, Christopher ML, Tran JN, Kazerooni R, Morreale AP. Cost utility of tumour necrosis factor-a inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model. Pharmacoeconomics. 2012 Jul 01; 30(7):575-93.

View in: PubMed

People

Explore

Similar Concepts

Top Journals